Hudson Bay Capital Management
EW icon

Hudson Bay Capital Management’s Edwards Lifesciences EW Stock Holding History

Hudson Bay Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-32,100
Closed -$1.49M – 848
2018
Q1 		$1.49M Buy
+32,100
New +$1.39M 0.03% 503

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Hudson Bay Capital Management's EW Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Edwards Lifesciences (EW) stake by 83% in Q2 2026, selling an estimated $37.1M and leaving 89,100 shares worth $8.06M. The position accounts for 0.02% of the portfolio, ranked #419.

Hudson Bay Capital Management first reported a position in EW in Q1 2018 and has held it in 6 quarters since. The position peaked at $73.1M in Q2 2025. 1,337 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Hudson Bay Capital Management held 89,100 shares of Edwards Lifesciences worth $8.06M as of Q2 2026.
  • Hudson Bay Capital Management sold 443,000 Edwards Lifesciences shares in Q2 2026, an estimated $37.1M.
  • Edwards Lifesciences made up 0.02% of Hudson Bay Capital Management's portfolio in Q2 2026, its #419 holding.
  • Hudson Bay Capital Management first reported a position in Edwards Lifesciences in Q1 2018 and has held it in 6 quarters since.
  • Hudson Bay Capital Management's Edwards Lifesciences position peaked at $73.1M in Q2 2025.
  • 1,337 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.